Ticker
ADAG

Price
1.84
Stock movement down
-0.05 (-2.65%)
Company name
Adagene Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
79.90M
Ent verdi
-22.26M
Pris/omsetning
-
Pris/bok
0.71
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-74.86%
3 års avkastning
-
5 års avkastning
-
10 års avkastning
-
Sist oppdatert: 2023-02-02

UTBYTTE

ADAG betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning-
Pris til bok0.71
EV i forhold til salg-

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall43.42M
EPS (TTM)-
FCF per aksje (TTM)-

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)0.00
Bruttofortjeneste (TTM)0.00
Driftsinntekter (TTM)0.00
Netto inntekt (TTM)0.00
EPS (TTM)-
EPS (1 år fremover)-2.14

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenestemargin (TTM)-

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter168.04M
Netto fordringer1.87M
Samlede omløpsmidler175.01M
Goodwill0.00
Immaterielle eiendeler0.00
Eiendom, anlegg og utstyr0.00
Sum eiendeler178.56M
Leverandørgjeld4.67M
Kortsiktig/nåværende langsiktig gjeld17.00M
Sum kortsiktig gjeld56.46M
Sum gjeld65.87M
Aksjonærenes egenkapital112.68M
Netto varige driftsmidler112.68M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)0.00
Kapitalutgifter (TTM)0.00
Fri kontantstrøm (TTM)0.00
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-
Avkastning på eiendeler-
Avkastning på investert kapital-
Kontantavkastning på investert kapital-

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning2.00
Daglig høy2.00
Daglig lav1.83
Daglig volum48K
Tidenes høyeste29.60
1 år analytikerestimat13.83
Beta-
EPS (TTM)-
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon30 Mar 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ADAGS&P500
Nåværende prisfall fra toppnotering-93.78%-12.75%
Høyeste prisfall-96.96%-56.47%
Dato for høyeste fall31 Oct 20229 Mar 2009
Gj.snittlig fall fra topp-71.78%-11.49%
Gj.snittlig tid til ny topp250 days13 days
Maks tid til ny topp498 days1805 days
SELSKAPSOPPLYSNINGER
ADAG (Adagene Inc) company logo
Markedsverdi
79.90M
Markedsverdi kategori
Small-cap
Beskrivelse
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Ansatte
259
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
USA
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
- No dose-limiting toxicities observed when ADG126 combined up to 10 mg/kg with repeat cycles, highlighting compelling safety profile with SAFEbody precision masking technology - - Partial responses c...
9. januar 2023
SAN DIEGO and SUZHOU, China, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announce...
5. januar 2023
SAN DIEGO and SUZHOU, China, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announce...
16. desember 2022
SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announce...
21. november 2022
- Interim phase 1b/2 data report safety profile of ADG116 across dosing levels, with repeat dosing of more than four cycles both as monotherapy and in combination with anti-PD-1 therapy - - Results in...
10. november 2022
- NEObody technology platform enables dynamic targeting of a distinct epitope of CTLA-4 for enhanced safety and efficacy - - Data from phase 1b/2 studies in heavily pre-treated patients showcase diffe...
11. oktober 2022
- Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady accumulation of activated ADG126 - - On track in 2022 to report re...
10. september 2022
– Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be pre...
30. august 2022
SAN DIEGO and SUZHOU, China, June 29, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today an...
29. juni 2022
Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced the publication of data showing the potential best-in-c...
27. mai 2022
Neste side